Phospho-MARCKS (Ser158) Antibody [D19L10]

Katalog-Nr. F2837

Drucken

Biologische Beschreibung

Spezifität

Phospho-MARCKS (Ser158) Antibody [D19L10] detektiert endogene MARCKS-Spiegel nur, wenn Serin 158 phosphoryliert ist.

Hintergrund MARCKS (myristoylated alanine-rich C kinase substrate) ist ein ubiquitär exprimiertes, evolutionär konserviertes, nativ entfaltetes Protein und ein Hauptsubstrat konventioneller und neuer PKC-Isoformen. Strukturell enthält es drei konservierte Domänen: eine N-terminale Myristoylierungsstelle (für die Membranverankerung), eine zentrale Lysin-reiche Effektor-Domäne (ED; aa 151–175), die Actin, Ca²⁺/Calmodulin und PIP₂ bindet, und die MH2-Domäne unbekannter Funktion. MARCKS assoziiert mit der Plasmamembran sowohl durch hydrophobe Myristat-Insertion als auch durch elektrostatische Effektor-Domänen-PIP₂-Interaktionen, ein Prozess, der durch den „Myristoyl-elektrostatischen Schalter“ reguliert wird. Die PKC-vermittelte Phosphorylierung der Effektor-Domäne (insbesondere an Serin 158). PMA erhöhte die Phosphorylierung des MARCKS-Proteins an Serin 158, einer Stelle innerhalb seiner Effektor-Domäne, die von PKC angegriffen wird, signifikant, was die PKC-vermittelte Regulation der Membranassoziation von MARCKS und der Actin-Bindungsaktivität widerspiegelt, wodurch MARCKS in das Zytosol transloziert und die Reorganisation des Actin-Zytoskeletts, die Adhäsion, Migration und Exozytose moduliert. Hoch exprimiert in allen eukaryotischen Zellen (wobei MARCKSL1 im Gehirn, in Fortpflanzungsgeweben und Makrophagen angereichert ist), ist MARCKS essenziell für die embryonale Entwicklung und neuronale Funktionen. Seine Dysregulation trägt zu entzündlichen, allergischen und neoplastischen Atemwegserkrankungen wie COPD, Asthma, ARDS und Lungenkrebs bei, was es zu einem wichtigen „medikamentösen“ Ziel macht.

Nutzungsinformationen

Anwendung WB Verdünnung
WB
1:1000 - 1:10000
Reaktivität Human, Mouse, Rat
Quelle Rabbit Monoclonal Antibody MW 32 kDa
Lagerpuffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Lagerung
(Ab dem Datum des Erhalts)
-20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail),and homogenize the tissue at a low temperature.
2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail) and put the sample on ice for 5 min.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail) and put the sample on ice for 5 min.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 60 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution ( recommending 5% BSA solution) for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

Referenzen

  • https://pubmed.ncbi.nlm.nih.gov/30339463/
  • https://pubmed.ncbi.nlm.nih.gov/35418879/

Anwendungsdaten

WB

Validiert von Selleck

  • F2837-wb
    Lane 1: HEK293 (treated with TPA-treated), Lane 2: HEK293 (TPA-treated; lambda phosphatase-treated)